Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
17-20 March, 2025
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Not Confirmed
Not Confirmed
03-05 January, 2025
Not Confirmed
Not Confirmed
07-09 January, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
17-20 March, 2025
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Industry Trade Show
Not Confirmed
03-05 January, 2025
Industry Trade Show
Not Confirmed
07-09 January, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-bora-polpharma-make-acquisitions-evonik-euroapi-porton-announce-technological-expansions
11 Dec 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/12/11/2995201/0/en/Serina-Therapeutics-to-Present-at-the-3rd-Annual-LNP-Immunogenicity-Toxicity-Summit.html
02 Dec 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/12/02/2990192/0/en/Serina-Therapeutics-Secures-10-Million-Financing-to-Continue-Advancing-Lead-IND-Candidate-into-Phase-1-Clinical-Trial-in-Advanced-Parkinson-s-Disease-Patients.html
12 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/12/2979797/0/en/Serina-Therapeutics-Reports-Third-Quarter-2024-Financial-Results-and-Provides-Business-Highlights.html
11 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/11/2978620/0/en/Serina-Therapeutics-Makes-Grants-to-New-Employees-Under-Inducement-Plan.html
02 Oct 2024
// GLOBENEWSWIRE
https://www.globenewswire.com//en/news-release/2024/10/02/2956954/0/en/Serina-Therapeutics-to-Present-at-the-14th-Annual-Injectables-Summit.html
04 Sep 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/09/04/2940971/0/en/Serina-Therapeutics-to-Present-at-the-H-C-Wainwright-26th-Annual-Global-Investment-Conference.html
Details:
The combined company will focus on advancing IND-enabling studies of Serina’s lead drug candidate SER-252 (POZ-apomorphine) for treatment of Parkinson’s Disease, and expanding POZ Platform.
Lead Product(s): POZ-Apomorphine
Therapeutic Area: Neurology Brand Name: SER-252
Study Phase: IND EnablingProduct Type: Small molecule
Recipient: Enable Injections
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 15, 2024
Lead Product(s) : POZ-Apomorphine
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Recipient : Enable Injections
Deal Size : Undisclosed
Deal Type : Agreement
Enable Injections and Serina to Develop SER-252 for Advanced Parkinson's Disease
Details : The combined company will focus on advancing IND-enabling studies of Serina’s lead drug candidate SER-252 (POZ-apomorphine) for treatment of Parkinson’s Disease, and expanding POZ Platform.
Brand Name : SER-252
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 15, 2024
Details:
The combined company will focus on advancing pre-clinical studies of Serina’s lead drug candidate SER-252 (POZ-apomorphine) for treatment of Parkinson’s Disease, and expanding POZ Platform.
Lead Product(s): POZ-Apomorphine
Therapeutic Area: Neurology Brand Name: SER-252
Study Phase: PreclinicalProduct Type: Small molecule
Recipient: AgeX Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger March 26, 2024
Lead Product(s) : POZ-Apomorphine
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Recipient : AgeX Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics
Details : The combined company will focus on advancing pre-clinical studies of Serina’s lead drug candidate SER-252 (POZ-apomorphine) for treatment of Parkinson’s Disease, and expanding POZ Platform.
Brand Name : SER-252
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 26, 2024
Details:
The agreement provides access to Serina's POZ polymer technology for potential use in lipid nanoparticle (LNP) formulations for RNA-based therapeutics.
Lead Product(s): RNA-based Therapeutic
Therapeutic Area: Technology Brand Name: Undisclosed
Study Phase: Discovery PlatformProduct Type: Large molecule
Sponsor: Pfizer Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 17, 2023
Lead Product(s) : RNA-based Therapeutic
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Serina Therapeutics Announces POZ Polymer Technology License Agreement with Pfizer
Details : The agreement provides access to Serina's POZ polymer technology for potential use in lipid nanoparticle (LNP) formulations for RNA-based therapeutics.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
November 17, 2023
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?